Long-term treatment with rituximab is feasible in selected patients with B-CLL: Response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy

Leukemia and Lymphoma

Volumn 48, Issue 5, 2007, Pages 905-911

  Srock, Stefanie ^a   Schriever, Folke ^b   Neubauer, Andreas ^c   Herold, Michael ^d   Huhn, Dieter ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Hämatologisch onkologische Praxis ^*  (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d HELIOS KLINIKUM ERFURT   (Germany)

^e Meoclinic   (Germany)

Author keywords

B cell chronic lymphocytic leukemia; Maintenance treatment; Rituximab

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GEMCITABINE; IMMUNOGLOBULIN; LOMUSTINE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CHILL; CHOLECYSTITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEMALE; HERPES; HUMAN; HYPOTENSION; INFECTION; INSOMNIA; LEUKEMIA RELAPSE; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OTITIS; PAIN; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SKIN INFECTION; T LYMPHOCYTE SUBPOPULATION; TACHYCARDIA; THROMBOCYTE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTES; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 34547483328     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701225874     Document Type: Article

References (12)

1. Plosker, G. L. (2003) Rituximab, a review of its use in non-Hodgkin's lymhoma and chronic lymphocytic leukaemia. Drugs, 63, pp. 803-843.
2. Huhn, D. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 98, pp. 1326-1331.
3. O'Brien, S. M. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol, 19, pp. 2165-2170.
4. Byrd, J. C. (2001) Rituximab using thrice weekly dosing schedule in B-CLL and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol, 19, pp. 2153-2164.
5. Hainsworth, J. D. (2003) Single-agent rituximab as first-line and maintenance treatment for patients with CLL or small lymphocytic lymphoma. J Clin Oncol, 21, pp. 1746-1751.
6. McLaughlin, P. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
7. Keating, M. J. (2002) Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol, 29, pp. 70-74.
8. Cheson, B. D. (1996) National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood, 87, pp. 4990-4997.
9. Golay, J., Lazzari, M. and Faccinatti, V. (2001) CD 20 levels determine the in vitro susceptibility to rituximab and complement of B cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood, 98, pp. 3383-3389.
10. Jilani, I. (2003) Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood, 102, pp. 3514-3520.
11. Manshouri, T., Do, Kim-anh and Wang, X. (2003) Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood, 101, pp. 2507-2513.
12. Gordan, L. N., Grow, W. B. and Pusateri, A. (2005) Phase 2 trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol, 23, pp. 1096-1102.